12:00 AM
 | 
Sep 29, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Atacand candesartan cilexetil: Phase III data

In the 4-year, double-blind, international Phase III DIRECT-Prevent 1 trial in 1,421 Type 1 diabetics without retinopathy, Atacand narrowly missed the primary endpoint of significantly lowering the incidence of retinopathy defined as >=2-step increase on...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >